Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)

NCT02387957 is registered in ClinicalTrials.gov with Ophthotech Corporation as lead sponsor.

NCT NCT02387957
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02387957 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24 Month Phase 2a Open Label, Randomized Study of Avastin®, Lucentis®, or Eylea® (Anti-VEGF Therapy) Administered in Combination With Fovista® (Anti-PDGF BB Pegylated Aptamer)
Lead sponsor
Ophthotech Corporation
Phase
Phase 2
Overall status
Terminated
Start date
April 26, 2016
Completion date
January 31, 2017
Enrollment
63 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

age-related macular degeneration